TDF/FTC/RPV 作为 HIV 暴露后预防:多中心前瞻性研究结果
本研究在法国五家 HIV 中心前瞻性观察 TDF/FTC/RPV 单片制剂用于职业与非职业暴露后预防的耐受性、完成率及 HIV 血清学转换。163 例暴露后预防中 86.1% 完成 28 天疗程,69.6% 报告至少一种不良事件但多为轻中度,第 16 周无 HIV 血清学转换,支持现行法国指南推荐。
要点
- TDF/FTC/RPV 单片制剂 28 天方案完成率 86.1%,提前中断率低。
- 69.6% 报告至少一种不良事件,多为轻中度,无严重不良事件或肝肾毒性。
- 第 16 周随访无 HIV 血清学转换,支持该方案用于暴露后预防。
核心结论
- 低提前中断率、良好耐受性及无 documented HIV 血清学转换支持现行法国指南推荐 TDF/FTC/RPV 28 天方案用于性及非性暴露后预防。
研究设计与样本
- 观察性、前瞻性、多中心、开放标签、非随机研究,在法国五家 HIV 中心开展。
- 2016 年 3 月至 2017 年 3 月共 163 例暴露后预防,其中 150 例为性暴露(44% 异性恋、56% MSM),13 例为非性暴露。
- 成人按法国国家指南接受 TDF/FTC/RPV 每日一片共 28 天,第 4 周评估临床与生物学耐受性,第 16 周后评估 HIV 血清学转换。
主要发现
- 5 例因源患者 HIV 阴性在数日后停止暴露后预防,剩余 158 例中 15 例(9.5%)第 4 周失访。
- 7 例(4.4%)提前中断暴露后预防,原因包括患者决定/不依从(n=3)或不良事件(胃肠道不耐受 n=3、乏力 n=1)。
- 136 例(86.1%)完成 28 天治疗;总体 69.6% 报告至少一种不良事件,多为轻中度,无严重不良事件或肝肾功能毒性。
- 第 16 周无 HIV 血清学转换发生。
临床怎么用
- 对于符合法国国家指南的成人暴露后预防,可考虑 TDF/FTC/RPV 单片制剂每日一次共 28 天。
- 需关注胃肠道不耐受和乏力等不良事件,但多为轻中度,无严重不良事件或肝肾毒性报道。
- 应加强随访以减少失访,并在第 16 周后评估 HIV 血清学转换。
局限性
- 观察性、非随机、开放标签设计,无对照组。
- 样本量 163 例暴露后预防,第 4 周失访 15 例(9.5%)。
- 仅五家法国 HIV 中心,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Since 2016, French guidelines have recommended the single-tablet regimen of tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)/rilpivirine (RPV) as HIV post-exposure prophylaxis (PEP), but few data support this usage. We evaluated the tolerability, treatment completion and occurrence of HIV seroconversion associated with this combination in occupational and non-occupational PEP. PATIENTS AND METHODS: We conducted an observational, prospective, multicentre, open-label, non-randomized study in five French HIV centres. Adults requiring PEP according to national French guidelines were prescribed TDF/FTC/RPV one pill once a day for 28 days. Clinical and biological tolerability was assessed at week 4; occurrence of HIV seroconversion was evaluated after week 16. RESULTS: From March 2016 to March 2017, 163 courses of PEP were prescribed for 150 sexual exposures (44% heterosexual and 56% MSM) and 13 non-sexual exposures. Five participants stopped PEP after a few days because the source person was HIV uninfected. Of the remaining 158 individuals, 15 (9.5%) were lost to follow-up at week 4, 7 (4.4%) prematurely discontinued PEP [patient's decision/non-adherence (n = 3) or adverse events (gastrointestinal intolerance n = 3, fatigue n = 1)] and 136 (86.1%) completed the 28 day treatment. Overall, 69.6% of participants declared at least one adverse event, mostly of mild to moderate intensity and no serious adverse events or hepatic or renal toxicity occurred. No HIV seroconversion occurred at week 16. CONCLUSIONS: The low rate of premature treatment interruption, the good tolerability and the absence of documented HIV seroconversion support the current French guidelines of a 28 day course of TDF/FTC/RPV for sexual and non-sexual PEP.
引用
- Chauveau M, Billaud E, Bonnet B, et al. Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study. J Antimicrob Chemother. 2019. PMID: 30689937. doi:10.1093/jac/dky547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。